Literature DB >> 8192436

New quinolones and gram-positive bacteria.

L J Piddock1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8192436      PMCID： PMC284419          DOI： 10.1128/AAC.38.2.163

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  37 in total

Review 1.  The molecular basis of quinolone action.

Authors:  A Maxwell
Journal:  J Antimicrob Chemother       Date:  1992-10       Impact factor: 5.790

2.  The accumulation of five quinolone antibacterial agents by Escherichia coli.

Authors:  J M Diver; L J Piddock; R Wise
Journal:  J Antimicrob Chemother       Date:  1990-03       Impact factor: 5.790

3.  New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.

Authors:  J M Domagala; L D Hanna; C L Heifetz; M P Hutt; T F Mich; J P Sanchez; M Solomon
Journal:  J Med Chem       Date:  1986-03       Impact factor: 7.446

4.  Association between early inhibition of DNA synthesis and the MICs and MBCs of carboxyquinolone antimicrobial agents for wild-type and mutant [gyrA nfxB(ompF) acrA] Escherichia coli K-12.

Authors:  R T Chow; T J Dougherty; H S Fraimow; E Y Bellin; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

5.  Mechanism of action of lomefloxacin.

Authors:  L J Piddock; M C Hall; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  The in-vitro activity of PD127,391, a new quinolone.

Authors:  A King; C Boothman; I Phillips
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

7.  Routes of quinolone permeation in Escherichia coli.

Authors:  J S Chapman; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

8.  Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa.

Authors:  R E Hancock; V J Raffle; T I Nicas
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

9.  Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative.

Authors:  S R Norrby; M Jonsson
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

10.  In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.

Authors:  A L Barry; R N Jones
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790
View more
  33 in total

1.  Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.

Authors:  V J Heaton; C E Goldsmith; J E Ambler; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

2.  In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.

Authors:  M P Montanari; M Mingoia; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 3.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

4.  Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.

Authors:  X S Pan; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

5.  In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.

Authors:  T A Davies; G A Pankuch; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

6.  Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.

Authors:  J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

7.  Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.

Authors:  F L Alovero; X S Pan; J E Morris; R H Manzo; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

8.  Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.

Authors:  J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

9.  The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper.

Authors:  Andrew E Simor; Mark Loeb
Journal:  Can J Infect Dis       Date:  2004-01

10.  Activity of Bay y3118 against quinolone-susceptible and -resistant gram-negative and gram-positive bacteria.

Authors:  L J Piddock; A J Marshall; Y F Jin
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.